ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
Dong-Hoon Yeom, Yo-Seob Lee, Ilhwan Ryu, Sunju Lee, Byungje Sung, Han-Byul Lee, Dongin Kim, Jin-Hyung Ahn, Eunsin Ha, Yong-Soo Choi, Sang Hoon Lee, Weon-Kyoo You, Dong-Hoon Yeom, Yo-Seob Lee, Ilhwan Ryu, Sunju Lee, Byungje Sung, Han-Byul Lee, Dongin Kim, Jin-Hyung Ahn, Eunsin Ha, Yong-Soo Choi, Sang Hoon Lee, Weon-Kyoo You
Abstract
Delta-like-ligand 4 (DLL4) is a promising target to augment the effects of VEGF inhibitors. A simultaneous blockade of VEGF/VEGFR and DLL4/Notch signaling pathways leads to more potent anti-cancer effects by synergistic anti-angiogenic mechanisms in xenograft models. A bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) demonstrates more potent in vitro and in vivo biological activity compared to VEGF or DLL4 targeting monoclonal antibodies alone and is currently being evaluated in a phase 1 clinical study of heavy chemotherapy or targeted therapy pre-treated cancer patients (ClinicalTrials.gov Identifier: NCT03292783). However, the effects of a combination of ABL001 and chemotherapy on tumor vessels and tumors are not known. Hence, the effects of ABL001, with or without paclitaxel and irinotecan were evaluated in human gastric or colon cancer xenograft models. The combination treatment synergistically inhibited tumor progression compared to each monotherapy. More tumor vessel regression and apoptotic tumor cell induction were observed in tumors treated with the combination therapy, which might be due to tumor vessel normalization. Overall, these findings suggest that the combination therapy of ABL001 with paclitaxel or irinotecan would be a better clinical strategy for the treatment of cancer patients.
Keywords: VEGF; anti-angiogenesis; delta-like ligand; irinotecan; paclitaxel; therapeutic antibody.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
- Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 2008;358:2039–2049. doi: 10.1056/NEJMra0706596.
- Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9–22. doi: 10.1096/fasebj.13.1.9.
- Meadows K.L., Hurwitz H.I. Anti-VEGF therapies in the clinic. Cold Spring Harb. Perspect. Med. 2012;2:a006577. doi: 10.1101/cshperspect.a006577.
- Shams N., Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol. Clin. N. Am. 2006;19:335–344.
- Kaur H., Bruno J.G., Kumar A., Sharma T.K. Aptamers in the therapeutics and diagnostics pipelines. Theranostics. 2018;8:4016. doi: 10.7150/thno.25958.
- Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., Claesson-Welsh L., Janjic N. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165) inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 1998;273:20556–20567. doi: 10.1074/jbc.273.32.20556.
- Zhou B., Wang B. Pegaptanib for the treatment of age-related macular degeneration. Exp. Eye Res. 2006;83:615–619. doi: 10.1016/j.exer.2006.02.010.
- Ohr M., Kaiser P.K. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin. Pharmacother. 2012;13:585–591. doi: 10.1517/14656566.2012.658368.
- Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer. 2008;8:592–603. doi: 10.1038/nrc2442.
- Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232–239. doi: 10.1016/j.ccr.2009.01.021.
- Hashizume H., Falcón B.L., Kuroda T., Baluk P., Coxon A., Yu D., Bready J.V., Oliner J.D., McDonald D.M. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 2010;70:2213–2223. doi: 10.1158/0008-5472.CAN-09-1977.
- You W.-K., Sennino B., Williamson C.W., Falcón B., Hashizume H., Yao L.-C., Aftab D.T., McDonald D.M. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011;71:4758–4768. doi: 10.1158/0008-5472.CAN-10-2527.
- Gale N.W., Dominguez M.G., Noguera I., Pan L., Hughes V., Valenzuela D.M., Murphy A.J., Adams N.C., Lin H.C., Holash J., et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl. Acad. Sci. USA. 2004;101:15949–15954. doi: 10.1073/pnas.0407290101.
- Noguera-Troise I., Daly C., Papadopoulos N.J., Coetzee S., Boland P., Gale N.W., Lin H.C., Yancopoulos G.D., Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444:1032–1037. doi: 10.1038/nature05355.
- Sainson R.C., Harris A.L. Anti-Dll4 therapy: Can we block tumour growth by increasing angiogenesis? Trends Mol. Med. 2007;13:389–395. doi: 10.1016/j.molmed.2007.07.002.
- Miles K.M., Seshadri M., Ciamporcero E., Adelaiye R., Gillard B., Sotomayor P., Attwood K., Shen L., Conroy D., Kuhnert F., et al. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. PLoS ONE. 2014;9:e112371. doi: 10.1371/journal.pone.0112371.
- Kuramoto T., Goto H., Mitsuhashi A., Tabata S., Ogawa H., Uehara H., Saijo A., Kakiuchi S., Maekawa Y., Yasutomo K., et al. Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-κB activity. Mol. Cancer Ther. 2012;11:2578–2587. doi: 10.1158/1535-7163.MCT-12-0640.
- Jenkins D.W., Ross S., Veldman-Jones M., Foltz I.N., Clavette B.C., Manchulenko K., Eberlein C., Kendrew J., Petteruti P., Cho S., et al. MEDI0639: A novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol. Cancer Ther. 2012;11:1650–1660. doi: 10.1158/1535-7163.MCT-11-1027.
- Li J.-L., Sainson R.C., Oon C.E., Turley H., Leek R., Sheldon H., Bridges E., Shi W., Snell C., Bowden E.T., et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011;71:6073–6083. doi: 10.1158/0008-5472.CAN-11-1704.
- Kuhnert F., Chen G., Coetzee S., Thambi N., Hickey C., Shan J., Kovalenko P., Noguera-Troise I., Smith E., Fairhurst J., et al. Dll4 blockade in stromal cells mediates antitumor effects in preclinical models of ovarian cancer. Cancer Res. 2015;75:4086–4096. doi: 10.1158/0008-5472.CAN-14-3773.
- Hoey T., Yen W.-C., Axelrod F., Basi J., Donigian L., Dylla S., Fitch-Bruhns M., Lazetic S., Park I.-K., Sato A., et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell. 2009;5:168–177. doi: 10.1016/j.stem.2009.05.019.
- Marvin J.S., Zhu Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol. Sin. 2005;26:649–658. doi: 10.1111/j.1745-7254.2005.00119.x.
- Lee D., Kim D., Choi Y.B., Kang K., Sung E.-S., Ahn J.-H., Goo J., Yeom D.-H., Jang H.S., Moon K.D., et al. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. MAbs. 2016;8:892–904. doi: 10.1080/19420862.2016.1171432.
- Kim D.-H., Lee S., Kang H.G., Park H.-W., Lee H.-W., Kim D., Yoem D.-H., Ahn J.-H., Ha E., You W.-K., et al. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020;53:533. doi: 10.5483/BMBRep.2020.53.10.103.
- Lee J., Kim S., Lee S.J., Park S.H., Park J.O., Ha E., Park D.-H., Park N., Kim H.-K., Lee S.H., et al. Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer. J. Clin. Oncol. 2019;37:3023. doi: 10.1200/JCO.2019.37.15_suppl.3023.
- Teicher B.A. A systems approach to cancer therapy. Cancer Metastasis Rev. 1996;15:247–272. doi: 10.1007/BF00437479.
- Comunanza V., Bussolino F. Therapy for cancer: Strategy of combining anti-angiogenic and target therapies. Front. Cell Dev. Biol. 2017;5:101. doi: 10.3389/fcell.2017.00101.
- Wildiers H., Guetens G., De Boeck G., Verbeken E., Landuyt B., Landuyt W., De Bruijn E., Van Oosterom A. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer. 2003;88:1979–1986. doi: 10.1038/sj.bjc.6601005.
- Zhang Q., Bindokas V., Shen J., Fan H., Hoffman R.M., Xing H.R. Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents. Mol. Cancer Ther. 2011;10:1173–1184. doi: 10.1158/1535-7163.MCT-11-0008.
- Zirlik K., Duyster J. Anti-angiogenics: Current situation and future perspectives. Oncol. Res. Treat. 2018;41:166–171. doi: 10.1159/000488087.
- Jászai J., Schmidt M.H. Trends and challenges in tumor anti-angiogenic therapies. Cells. 2019;8:1102. doi: 10.3390/cells8091102.
- Han J., Gao L., Wang J., Wang J. Application and development of aptamer in cancer: From clinical diagnosis to cancer therapy. J. Cancer. 2020;11:6902. doi: 10.7150/jca.49532.
- Kang M., Jiang B., Xu B., Lu W., Guo Q., Xie Q., Zhang B., Dong X., Chen D., Wu Y. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. Cancer Lett. 2013;330:11–21. doi: 10.1016/j.canlet.2012.11.015.
- Mancuso M.R., Davis R., Norberg S.M., O’Brien S., Sennino B., Nakahara T., Yao V.J., Inai T., Brooks P., Freimark B., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Investig. 2006;116:2610–2621. doi: 10.1172/JCI24612.
- Li J.-L., Harris A.L. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: Therapeutic implications. Front. Biosci. (Landmark Ed.) 2009;14:3094–3110. doi: 10.2741/3438.
- Mpekris F., Voutouri C., Baish J.W., Duda D.G., Munn L.L., Stylianopoulos T., Jain R.K. Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc. Natl. Acad. Sci. USA. 2020;117:3728–3737. doi: 10.1073/pnas.1919764117.
- Campesato L.F., Merghoub T. Antiangiogenic therapy and immune checkpoint blockade go hand in hand. Ann. Transl. Med. 2017;5:497. doi: 10.21037/atm.2017.10.12.
- Tang J., Shalabi A., Hubbard-Lucey V. Comprehensive analysis of the clinical immuno-oncology landscape. Ann. Oncol. 2018;29:84–91. doi: 10.1093/annonc/mdx755.
- Yu J.X., Hodge J.P., Oliva C., Neftelinov S.T., Hubbard-Lucey V.M., Tang J. Trends in clinical development for PD-1/PD-L1 inhibitors. Nat. Rev. Drug Discov. 2020;19:163–164.
- Socinski M.A., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodríguez-Abreu D., Moro-Sibilot D., Thomas C.A., Barlesi F. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 2018;378:2288–2301. doi: 10.1056/NEJMoa1716948.
- Motzer R.J., Penkov K., Haanen J., Rini B., Albiges L., Campbell M.T., Venugopal B., Kollmannsberger C., Negrier S., Uemura M. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 2019;380:1103–1115. doi: 10.1056/NEJMoa1816047.
- Rini B.I., Plimack E.R., Stus V., Gafanov R., Hawkins R., Nosov D., Pouliot F., Alekseev B., Soulières D., Melichar B. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 2019;380:1116–1127. doi: 10.1056/NEJMoa1816714.
- Finn R.S., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.-Y., Kudo M., Breder V., Merle P., Kaseb A.O. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 2020;382:1894–1905. doi: 10.1056/NEJMoa1915745.
Source: PubMed